Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Park, Jong Sun ^a   Park, Hyo Jin ^a   Park, Young Sik ^b   Lee, Sang Min ^b   Yim, Jae Joon ^b   Yoo, Chul Gyu ^b   Han, Sung Koo ^b   Kim, Young Whan ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Immunohistochemical analysis; Mtor; Pulmonary fibrosis; Rock1; Survival; Usual interstitial pneumonia; Zeb1

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOTRANSFERASE; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE 1; STEROID; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; CARBON MONOXIDE; HOMEODOMAIN PROTEIN; MTOR PROTEIN, HUMAN; RHO KINASE; ROCK1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CARBON MONOXIDE DIFFUSION CAPACITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONNECTIVE TISSUE DISEASE RELATED INTERSTITIAL LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ANALYSIS; FEMALE; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS EPITHELIUM CELL; LUNG BIOPSY; LUNG FIBROSIS; LUNG INSUFFICIENCY; LUNG PARENCHYMA; LUNG SURGERY; MALE; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RESPIRATORY TRACT PARAMETERS; SCORING SYSTEM; CHEMISTRY; LUNG ALVEOLUS; LUNG DIFFUSION CAPACITY; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RESPIRATORY TRACT MUCOSA;

ADULT; AGED; CARBON MONOXIDE; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY ALVEOLI; PULMONARY DIFFUSING CAPACITY; RESPIRATORY MUCOSA; RHO-ASSOCIATED KINASES; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 84920766985     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-168     Document Type: Article

References (26)

1. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011, 378(9807):1949-1961.
2. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007, 82(4):381-388.
3. Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, Hardie WD. Rapamycin prevents transforming growth factor-alphainduced pulmonary fibrosis. Am J Respir Cell Mol Biol 2009, 41(5):562-572.
4. Buschhausen L, Kamm M, Arns W, Schulze-Lohoff E, Weber M. [Successful treatment of a severe case of idiopathic pulmonary fibrosis with rapamycin]. Med Klin (Munich) 2005, 100(3):161-164.
5. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10(5):593-601.
6. Cho JH, Gelinas R, Wang K, Etheridge A, Piper MG, Batte K, Dakhallah D, Price J, Bornman D, Zhang S, March C, Galas D. Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes. BMC Med Genomics 2011, 4:8.
7. Shimizu Y, Dobashi K, Iizuka K, Horie T, Suzuki K, Tukagoshi H, Nakazawa T, Nakazato Y, Mori M. Contribution of small GTPase Rho and its target protein rock in a murine model of lung fibrosis. Am J Respir Crit Care Med 2001, 163(1):210-217.
8. American Thoracic Society/European Respiratory Society : American Thoracic Society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002, 165(2):277-304.
9. Park YS, Park CM, Lee HJ, Goo JM, Chung DH, Lee SM, Yim JJ, Kim YW, Han SK, Yoo CG: Clinical implication of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Respir Med 2013, 107(2):256-262.
10. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988, 41(4):467-470.
11. Akira M, Sakatani M, Ueda E. Idiopathic pulmonary fibrosis: progression of honeycombing at thin-section CT. Radiology 1993, 189(3):687-691.
12. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005, 17(6):596-603.
13. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006, 17(5):1395-1404.
14. Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006, 69(11):2029-2036.
15. Kramer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H, Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 2008, 294(2):F440-449.
16. Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011, 55(2):388-398.
17. Mehrad B, Burdick MD, Strieter RM. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009, 41(8-9):1708-1718.
18. Simler NR, Howell DC, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ, Chambers RC, Egan JJ. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 2002, 19(6):1124-1127.
19. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012, 380(9842):680-688.
20. Nair RV, Huang X, Shorthouse R, Adams B, Brazelton T, Braun-Dullaeus R, Morris RE. Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc 1997, 29(1-2):614-615.
21. GaoY, XuX, DingK, Liang Y, JiangD, Dai H: Rapamycin inhibits transforming growth factor beta1-induced fibrogenesis in primary human lung fibroblasts. Yonsei Med J 2013, 54(2):437-444.
22. Clinicaltrials.gov, A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT01462006?term=mTOR%2C+idiopathic +pulmonary+fibrosis&rank=1.
23. ten Dijke P, Hill CS: New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004, 29(5):265-273.
24. Aigner K, Descovich L, Mikula M, Sultan A, Dampier B, Bonne S, van Roy F, Mikulits W, Schreiber M, Brabletz T, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A. The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett 2007, 581(8):1617-1624.
25. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoAdependent mechanism. MolBiolCell 2001, 12(1):27-36.
26. Das S, Becker BN, Hoffmann FM, Mertz JE. Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway. BMC Cell Biol 2009, 10:94.